Standout Papers

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an o... 2021 2026 2022 2024166
  1. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial (2021)
    Assuntina G. Sacco, Ruifeng Chen et al. The Lancet Oncology

Immediate Impact

48 standout
Sub-graph 1 of 22

Citing Papers

A review on physics-informed data-driven remaining useful life prediction: Challenges and opportunities
2024 Standout
Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets
2024 Standout
2 intermediate papers

Works of Ruifeng Chen being referenced

Abstract P3-10-18: Phase 1b trial of cirmtuzumab and paclitaxel for locally advanced, unresectable and metastatic breast cancer
2020
Reducing uncertainty in time domain fatigue analysis of offshore structures using control variates
2020

Author Peers

Author Last Decade Papers Cites
Ruifeng Chen 164 92 161 28 519
Guillaume de La Bourdonnaye 53 46 253 25 538
Wojciech Dudek 78 143 49 67 612
Michael Esposito 155 177 37 46 612
Uri Zaretsky 35 94 83 39 557
Enrico de Campora 144 128 116 34 612
Grace Makari‐Judson 286 59 120 32 611
Kanako Azuma 164 64 51 23 501
Mi Du 33 33 31 35 526
Ronit Brodie 126 89 48 21 595
Mark Gormley 163 150 49 25 589

All Works

Loading papers...

Rankless by CCL
2026